Innovations in medical care and mortality trends from four circulatory diseases between 1970 and 2005

European Journal of Public Health

Volumn 23, Issue 5, 2013, Pages 852-857

  Hoffmann, Rasmus ^a   Plug, Iris ^a   McKee, Martin ^b   Khoshaba, Bernadette ^b   Westerling, Ragnar ^c   Looman, Caspar ^a   Rey, Gregoire ^d   Jougla, Eric ^d   Luis Alfonso, Jose ^e   Lang, Katrin ^f   Pärna, Kersti ^f   Mackenbach, Johan P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

^d INSERM   (France)

^e UNIVERSITY OF VALENCIA   (Spain)

^f UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; ESTONIA; EUROPE; EXPERIMENTAL THERAPY; FRANCE; GERMANY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MORTALITY; NETHERLANDS; QUESTIONNAIRE; SPAIN; SWEDEN; TIME; UNITED KINGDOM;

CAUSE OF DEATH; CEREBROVASCULAR DISORDERS; ESTONIA; EUROPE; FRANCE; GERMANY; GREAT BRITAIN; HEART FAILURE; HUMANS; HYPERTENSION; MORTALITY; MYOCARDIAL ISCHEMIA; NETHERLANDS; QUESTIONNAIRES; SPAIN; SWEDEN; THERAPIES, INVESTIGATIONAL; TIME FACTORS;

EID: 84880574393     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckt026     Document Type: Article

References (39)

1. Carr-Hill RA, Hardman GF, Russell IT. Variations in avoidable mortality and variations in health care resources. Lancet 1987;1:789-92.
2. Charlton JR, Velez R. Some international comparisons of mortality amenable to medical intervention. Br Med J (Clin Res Ed) 1986;292:295-301.
3. Mackenbach JP, Looman CW, Kunst AE, et al. Post-1950 mortality trends and medical care: gains in life expectancy due to declines in mortality from conditions amenable to medical intervention in The Netherlands. Soc Sci Med 1988;27:889-94.
4. Mackenbach JP, Bouvier-Colle MH, Jougla E. Avoidable mortality and health services: A review of aggregate data studies. J Epidemiol Commun H 1990;44:106-11.
5. Westerling R. Studies of avoidable factors influencing death: A call for explicit criteria. Qual Health Care 1996;5:159-65.
6. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. Br Med J 2005;331:614-17.
7. Meerding WJ, Polder JJ, Hollander dAEM, Mackenbach JP. Hoe Gezond Zijn de Zorguitgaven? Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu, 2007.
8. Goldman L, Cook EF. The decline in ischemic-heart-disease mortality-rates-an analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Int Med 1984;101:825-36.
9. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999;81:380-6.
10. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990-The effect of secular trends in risk factors and treatment. JAMA 1997;277:535-42.
11. Bots ML, Grobbee DE. Decline of coronary heart disease mortality in The Netherlands from 1978 to 1985: contribution of medical care and changes over time in presence of major cardiovascular risk factors. J Cardiovasc Risk 1996;3:271-6.
12. Barker WH, Mullooly JP, Linton KLP. Trends in hypertension prevalence, treatment, and control-In a well-defined older population. Hypertension 1998;31: 552-9.
13. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br Med J 1996;313:652-9.
14. Estess JM, Topol EJ. Fibrinolytic treatment for elderly patients with acute myocardial infarction. Heart 2002;87:308-11.
15. Jackson EA, Sullman SA. Comparative review of beta-blocking agents. Conn Med 1984;48:213-15.
16. May GS, Eberlein KA, Furberg CD, et al. Secondary prevention after myocardial-infarction-a review of long-term trials. Prog Cardiovasc Dis 1982;24: 331-52.
17. Mather HG, Morgan DC, Pearson NG, et al. Myocardial-infarction-comparison between home and hosputal-care for patients. Br Med J 1976;1:925-9.
18. Stern MP. Recent decline in ischemic heart-disease mortality. Ann Intern Med 1979; 91:630-40.
19. Neal B, MacMahon S, Chapman N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.
20. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet 2000;355:1575-1581.
21. Faris R, Flather MD, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev 2006;CD003838.
22. Whisnant JP. The decline of stroke. Stroke 1984;15:160-8.
23. Gifford RW. Long-term clinical trials in hypertension. J. Hypertens 1990;8: S17-S22.
24. Turnbull F, Neal B, Algert C, et al. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.
25. Benatru I, Rouaud O, Durier J, et al. Stable stroke incidence rates but improved case-fatality in Dijon, France, from 1985 to 2004. Stroke 2006;37: 1674-9.
26. Stegmayr B, Asplund K. Stroke in Northern Sweden. Scand J Public Health 2003;31: 60-9.
27. Ryan R, Gross N. The diffusion of hybrid seed corn in two Iowa communities. Rural Sociol 1943;8:15-24.
28. Rogers EM. Diffusion of Innovations. London: Free Press of Glencoe, 1962.
29. Rogers EM. Diffusion of preventive innovations. Addict Behav 2002;27:989-993.
30. Barendregt JJ, Looman CW, Bronnum-Hansen H. Comparison of cohort smoking intensities in Denmark and the Netherlands. Bull World Health Organ 2002;80: 26-32.
31. Otto SJ, Fracheboud J, Looman CW, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: A systematic review. Lancet 2003;361:1411-1417.
32. Rey G, Aouba A, Pavillon G, et al. Cause-specific mortality time series analysis: A general method to detect and correct for abrupt data production changes. Popul Health Metr 2011;9:52.
33. Zhang B, Su Z, Qiu P. On jump detection in regression curves using local polynomial kernel estimation. Pak J Stat 2009;25:505-28.
34. Hoffmann R, Plug I, Khoshaba B, et al. AMIEHS Working Group. Amenable mortality revisited: the AMIEHS study. Gac Sanit 2012. pii: S0213-9111.
35. Jougla E, Rossolin F, Niyonsenga A, et al. Comparability and Quality Improvement of European Causes of Death Statistics. European Commission, Brussels, DG Sanco, 2001.
36. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011;377:568-577.
37. Poikolainen K, Eskola J. The effect of health services on mortality: decline in death rates from amenable and non-amenable causes in Finland, 1969-81. Lancet 1986;1: 199-202.
38. Charlton JR, Hartley RM, Silver R, Holland WW. Geographical variation in mortality from conditions amenable to medical intervention in England and Wales. Lancet 1983;1(8326 Pt 1):691-6.
39. Mackenbach JP, Hoffmann R, Khoshaba B, et al. Using ?amenable mortality? as indicator of health care effectiveness in international comparisons: results of a validation study. J Epidemiol Community Health 2013;67:139-46.